Carregant...
Fitxers
Tipus de document
ArticleVersió
Versió publicadaData de publicació
Llicència de publicació
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/174260
ERBB2mRNA expression and response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-positive breast cancer
Títol de la revista
Director/Tutor
ISSN de la revista
Títol del volum
Recurs relacionat
Resum
Trastuzumab emtansine (T-DM1) is approved for the treatment of human epidermal growth factor receptor 2 (HER2)-positive (HER2+) metastatic breast cancer (BC) and for residual disease after neoadjuvant therapy; however, not all patients benefit. Here, we hypothesized that the heterogeneity in the response seen in patients is partly explained by the levels of human epidermal growth factor receptor 2 gene (ERBB2) mRNA.We analyzed ERBB2 expression using a clinically applicable assay in formalin-fixed para n-embedded (FFPE) tumors (primary or metastatic) from a retrospective series of 77 patients with advanced HER2+ BC treated with T-DM1. The association of ERBB2 levels and response was further validated in 161 baseline tumors from the West German Study (WGS) Group ADAPT phase II trial exploring neoadjuvant T-DM1 and 9 in vitro BC cell lines. Finally,
Matèries
Matèries (anglès)
Citació
Citació
GRIGUOLO, Gaia, BRASÓ MARISTANY, Fara, GONZÁLEZ FARRÉ, Blanca, PASCUAL, Tomás, CHIC RUCHÉ, Núria, SAURÍ, Tamara, KATES, Ronald, GLUZ, Oleg, MARTÍNEZ, Débora, PARÉ, Laia, TSVETKOVA, Vassilena, PESANTEZ, David, VIDAL LOSADA, Maria jesús, ADAMO, Barbara, MUÑOZ MATEU, Montserrat, GALVÁN, Patricia, BARBERÁ, Laura, CUATRECASAS FREIXAS, Miriam, CHRISTGEN, Mathias, KREIPE, Hans, MONGE ESCARTÍN, Inés, VILLAGRASA, Patricia, SOY MUNER, Dolors, GIARRATANO, Tommaso, DIECI, Maria vittoria, CONTE, Pierfranco, HARBECK, Nadia, GUARNERI, Valentina, PRAT APARICIO, Aleix. ERBB2mRNA expression and response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-positive breast cancer. _Cancers_. 2020. Vol. 12(7), núm. 1902. [consulta: 24 de gener de 2026]. ISSN: 2072-6694. [Disponible a: https://hdl.handle.net/2445/174260]